Clinical study to investigate recurrence efficacy on a combined use of radiofrequency ablation therapy and auto-gamma/delta T cell therapy for hepatitis C virus-related hepatocellular carcinoma patients.
Not Applicable
- Conditions
- Hepatitis C virus-related hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000004583
- Lead Sponsor
- Tokyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: - Active enteritis; - Active autoimmune diseases; - Active infections; - Other cancers; - Other serious complications; - Continuous systemic administration of steroids.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Recurrence-free survival rate
- Secondary Outcome Measures
Name Time Method Recurrence-free survival Overall survival Disease-specific survival Immunological responses Safety
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie gamma/delta T cell therapy synergy with radiofrequency ablation in HCV-related HCC?
How does combined radiofrequency ablation and gamma/delta T cell therapy compare to sorafenib in HCV-related hepatocellular carcinoma recurrence prevention?
Which biomarkers predict response to gamma/delta T cell therapy in hepatitis C virus-associated hepatocellular carcinoma patients?
What are the potential adverse events of auto-gamma/delta T cell therapy combined with radiofrequency ablation in liver cancer treatment?
Are there alternative immunotherapy combinations to gamma/delta T cells and radiofrequency ablation for HCV-related HCC recurrence?